Catalent Biologics (Catalent), a global contract development and manufacturing organization (CDMO), is a leader in providing comprehensive solutions for life sciences companies of all sizes. Catalent’s 19,000+ employees and approximately 2,500 scientists partner with pharma, biotech, and consumer health companies to optimize product development, launch, and full life-cycle supply for patients around the world.
Besides having a heavy hand in advancing the field of genomic medicines and solidifying the foundation for what has become the bustling I-270 Biotech Corridor, it’s clear that HGS has also had a major impact on the lives of those who worked there. BioBuzz in collaboration with Kymanox and BioIT Solutions recently hosted a HGS reunion event at True Respite Brewing Co., bringing together over 140 alumni of the organization. Some attendees even came in from out of state to catch up with former colleagues and friends that they haven’t seen in years.
The seas have been rough this year for the biotech and life sciences market, with funding scarcity and layoffs abound. The BioHealth Capital Region (BHCR) has braced the storm, though, holding tight to its fourth-place ranking on the Genetic & Engineering News (GEN) Top 10 Biopharma Clusters list. Alex Phillipidus, Senior Business Editor for GEN, gave the update at the eighth annual BioHealth Capital Region Forum.
Gaithersburg-based Neuroene Therapeutics and its approach to treating a rare form of epilepsy was crowned the winner of the seventh annual Crab Trap Competition, which highlights the commercialization potential of biohealth technologies throughout the BioHealth Capital Region.
In 2016, with a mission to improve client service, three patent lawyers—Susan McBee, C.G. Moore and David Vanik—came together along with 12 other professionals to form a new patent law firm, McBee Moore & Vanik, or MMVIP. Based in Maryland, the six-year-old firm works with clients that range from start-ups to large multinationals in scientific fields such as biotechnology, chemistry and pharmaceuticals. Seven practitioners hold PhDs, one holds an MD, and four are former United States Patent and Trademark Office (USPTO) examiners. Together, the team helps clients with everything from consultations during the initial phases of product development—such as identifying likely candidate inventions for patent protection—to obtaining patent rights, and defending those rights or challenging the patent rights of others.
The Manufacturing Assistance Program is designed to help growth-stage stem cell companies fund and build out their manufacturing capabilities, which is a major need, particularly among the Fund’s portfolio companies that have reached this stage in their development.
In 2019, Fulton Bank launched a new division aimed at supporting life sciences companies that many financial institutions shied away from historically—young, emerging bioscience and tech companies that offer high risk, high reward investment profiles.
Since its inception, MSCRF has invested over $170 million in over 500 projects to accelerate stem cell research, commercialization, and cures. With a 2023 fiscal year budget of $20.5M, MSCRF offers six funding opportunities to scientists and companies in the areas of clinical trials, discovery, commercialization, validation, launch, and post-doctoral fellowships. The fund has supported the creation and growth of many stem cell companies since launching the Accelerating Cures initiative in 2017.
There is no better way to get a glimpse into the future of the region’s life sciences ecosystem than the 8th annual BioHealth Capital Region (BHCR) Forum, which is fast approaching. The 2022 BHCR Forum is a can’t miss in-person/live streamed event hosted at United States Pharmacopeia (USP) in Rockville, Maryland on September 20th. Also, on September 21st at USP will be the 5th Annual BioHealth Capital Region Investment Conference and the 7th Annual Crab Trap Competition.
The Maryland Stem Cell Research Fund (MSCRF) is a champion for women in stem cell research. A host of women-led labs have received MSCRF support in pursuit of ground-breaking research in a wide-range of areas, including fields as diverse as blood brain barrier modeling, tissue engineering, autism, and rare disease therapeutics, among others.